MRK earnings: next report 2026-10-29, real EPS beat/miss history, analyst consensus Buy, P/E 35.82. Updated 2026-07-23.
Merck & (MRK) Research Hub
Merck & (MRK) trades on NYSE, US in the Healthcare (Drug Manufacturers - General) sector. As of 2026-09-11, shares last closed at 143.94 USD (-2.44%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 35.82, market cap 315.67B. This hub links to the full technical, earnings and options research available for MRK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - General) |
|---|---|
| Exchange | NYSE, US |
| Last close | 143.94 USD (-2.44%) |
| 52-week range | 113 USD – 156.92 USD |
| Trend regime | Range |
| 14-day RSI | 65.9 (Bullish) |
| Trailing P/E | 35.82 |
| Market cap | 315.67B |
| Dividend yield | 2.63% |
| Next earnings | 2026-10-29 |
Available research for MRK
Covered Call on MRK: how it works, illustrative setup around the real 143.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MRK: how it works, illustrative setup around the real 143.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MRK: how it works, illustrative setup around the real 143.94 USD price, max profit/loss, breakeven and when to use it. Educational.
MRK technical analysis: range, last 143.94 USD, RSI 65.9, 52w range 113 USD–156.92 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MRK in?
Merck & (MRK) is classified under Healthcare (Drug Manufacturers - General), listed on NYSE, US.
Is MRK in an uptrend or downtrend?
As of 2026-09-11, MRK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MRK's trailing P/E ratio?
MRK's trailing P/E is 35.82, with a market cap of 315.67B. See the earnings research page for full valuation detail.
When does MRK next report earnings?
MRK is next scheduled to report earnings on 2026-10-29, with a consensus EPS estimate of 2.27 USD.